Cardiac Troponin I after Carotid Endarterectomy in Different Cardiac Risk Patients

2015 ◽  
Vol 24 (3) ◽  
pp. 711-717 ◽  
Author(s):  
George Galyfos ◽  
Costas Tsioufis ◽  
Dimitris Theodorou ◽  
Stilianos Katsaragakis ◽  
Georgios Zografos ◽  
...  
Keyword(s):  
Carotid Endarterectomy ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Cardiac Risk ◽  
Cardiac Troponin I ◽  
Risk Patients ◽  
Cardiac Risk Patients

scholarly journals The Antibody Configurations of Cardiac Troponin I Assays May Determine Their Clinical Performance

2006 ◽  
Vol 52 (5) ◽  
pp. 832-837 ◽  
Author(s):  
Stefan James ◽  
Mats Flodin ◽  
Nina Johnston ◽  
Bertil Lindahl ◽  
Per Venge
Keyword(s):  
Monoclonal Antibodies ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Clinical Performance ◽  
Cardiac Troponin I ◽  
Unstable Coronary Artery Disease ◽  
Reference Limits ◽  
Risk Patients ◽  
Artery Disease ◽  
Roche Diagnostics

Abstract Background: Previous studies have shown superior clinical performance of the cardiac troponin I (cTnI) assay from Beckman-Coulter Diagnostics. This assay had a unique combination of monoclonal antibodies with 2 monoclonal antibodies directed against epitopes near the NH2 terminus of the heart-specific region of troponin I. The approach has been adopted by the new cTnI assay from Abbott Diagnostics. The aim of our study was to investigate whether this approach affects the clinical performance of cTnI assays. Methods: Cardiac troponin concentrations were measured in a random sample of patients with unstable coronary artery disease included in the GUSTO IV trial (n = 696) by the AccuTnI (Beckman-Coulter Diagnostics), Architect cTnI (Abbott Diagnostics), Immulite 2500 cTnI (Diagnostics Products Corporation), and Elecsys 2010 cTnT (Roche Diagnostics) assays and related to the 1-year mortality. The primary cutoff concentrations were based on the 99th percentile upper reference limits and an imprecision (CV) ≤10%. Results: The sensitivities of the AccuTnI and Architect cTnI assays in identifying patients who died within 1 year were equal and were significantly higher (P <0.05) than those of the Immulite 2500 cTnI and the Elecsys cTnT assays. The concordance between the AccuTnI and Architect cTnI assays was 97%, but concordances between the Architect cTnI and the Elecsys cTnT assays were 89%–92% with more at-risk patients (P <0.01 to P <0.001) identified by the Architect cTnI assay. Conclusions: The Architect cTnI assay has clinical performance similar to that of the AccuTnI, probably as a result of the inclusion of a monoclonal antibody against troponin I epitope 41–49 in the assay.

Outcome of low-risk patients discharged home after a normal cardiac troponin I

2004 ◽  
Vol 26 (4) ◽  
pp. 401-406 ◽  
Author(s):  
Stephen W Smith ◽  
Carrie D Tibbles ◽  
Fred S Apple ◽  
Marsha Zimmerman
Keyword(s):  
Cardiac Troponin ◽  
Troponin I ◽  
Cardiac Troponin I ◽  
Low Risk ◽  
Risk Patients

Abstract 16133: High Density Lipoprotein Cholesterol is an Alternative Marker to Troponin for Acute Coronary Syndrome in High Risk Patients

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Anke Nguyen ◽  
Heath Adams ◽  
Natalie Yap ◽  
Julian Gin ◽  
Andrew M Wilson
Keyword(s):  
High Risk ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Density Lipoprotein ◽  
Cardiac Troponin I ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Risk Patients

Introduction: It is well known that high density lipoprotein cholesterol is inversely correlated with the risk of coronary artery disease. However, data is limited regarding the relationship of high density lipoprotein cholesterol in the acute setting of coronary artery disease and particularly how it compares to the most well-known biomarker, cardiac troponin I. Hypothesis: We assessed the hypothesis that high density lipoprotein cholesterol could be used as an alternative marker to troponin for acute coronary syndrome (ACS) in high risk patients. Methods: We analysed 740 patients of the BRAVEHEART cohort presenting for coronary angiography at our institution between October 2009 and March 2014. Of these, 153 patients presented with ACS, including 44 with ST elevation myocardial infarction and 109 with non-ST elevation myocardial infarction, and 587 patients presented without ACS. Binary logistic regression was used to compare high density lipoprotein cholesterol and cardiac troponin I levels as predictors of ACS, independent of age, sex, cardiac risk factors and statin use. Results: Patients presenting with ACS had higher median cardiac troponin I levels (0.34 vs. 0.02 μg/L; p<0.001), higher median serum triglyceride levels (1.5 vs. 1.3 mmol/L, p<0.001) and lower median high density lipoprotein cholesterol levels (0.97 vs. 1.09 mmol/L, p<0.001) than patients without ACS. There was no difference in total cholesterol and low density lipoprotein cholesterol between the two groups. After adjusting for differences in patient variables, the strongest independent predictors of ACS were cardiac troponin I (odds ratio (OR), 1.50; 95% confidence interval (CI), 1.24-1.82; p<0.001) and high density lipoprotein cholesterol (OR, 0.12; 95% CI, 0.04-0.36; p<0.001). Conclusion: In conclusion, high density lipoprotein cholesterol was found to be an independent marker of ACS in high risk patients at our institution. Further studies on high density lipoprotein cholesterol could determine its clinical use in conjunction with troponin levels in patients presenting with ACS.

Sign in / Sign up

Export Citation Format

Share Document